Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

t tell B-cells to grow and divide, uncontrollably. This therapy can help stop cancer progression while preserving normal, healthy cells. Ibrutinib is a first in its class, oral therapy and is a new agent that inhibits the B-cell receptor signaling complex that plays an important role in the survival of malignant B-cells.  It is one of the first medicines to file for FDA approval via the new Breakthrough Therapy Designation pathway, bringing new hope to many suffering from CLL and other B-cell malignancies.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

We strive to be allies to all of our stakeholders – most importantly patients waging struggles against rare and incurable cancers – but also the physicians and family members who care for them, payers, our employees, our shareholders, and regulatory agencies working to bring life-changing medicines to patients.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDA
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Boston Scientific Corporation (NYSE: BSX ... purchase the Interventional business of Bayer AG. The ... offer physicians and healthcare systems a more complete ... The addition of the Bayer Interventional ... Boston Scientific strategy to provide a comprehensive portfolio ...
(Date:9/2/2014)... , Sept. 2, 2014  Volcano Corporation ... focused on improving patient and economic outcomes on ... minimally invasive coronary and peripheral visualization, physiology diagnostics ... participating in the Morgan Stanley Healthcare conference on ... Scott Huennekens , president and chief executive ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014  Arena ... that the US Food and Drug Administration (FDA) has ... of pulmonary arterial hypertension. "The FDA ... clinical data submissions from sponsors to identify and designate ... help advance the evaluation and development of such products," ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
(Date:9/2/2014)... CITY, GA (PRWEB) September 02, 2014 Last ... whole new level with the launch of a luxurious line ... to announce that the SEA ISLAND COTTON Socks are joining ... compression level, giving more people the comfort of natural cotton ... COTTON Socks, they are surprised to find socks as soft ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 Alliance ... targeting and multi-channel email marketing is pleased to announce ... market, Firearms & Freedom as well as ... properties represent more than one million concerned Americans who ... advertising. , “We are honored to continue providing ...
(Date:9/2/2014)... hospitalized, but your outpatient doctor does not know? ... follow-up care, but your doctor does not have ... Missing or incomplete communication from hospitals to outpatient ... experiences and lead to hospital readmissions. , ... can improve hospitals, communication during patient care transitions. ...
(Date:9/2/2014)... many health risks, including heart disease and diabetes, but ... to mitigate one often-overlooked risk: not buckling up in ... H. Jacobson, a professor of computer science and of ... with a decrease in seatbelt usage. However, these effects ... , "Primary seatbelt laws lead to increased use of ...
(Date:9/2/2014)... Farmington, New York (PRWEB) September 02, 2014 ... Millworks is making it easy to create a consistent look ... the physical structure, to the floor you walk on and ... shop for all custom reclaimed wood designs. , “We’re ... customers to our product line. It saves time, adds consistency, ...
Breaking Medicine News(10 mins):Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2
... The Advertising Standards Authority ruled yesterday that a Walkers ... salt content.// ,According to the industry watchdog ... in its crisps to "7% of your guideline daily ... did not apply to all Walkers crisps. They have ...
... scheme launched in Madhya Pradesh to help malnourished children is ... Shakti scheme was unveiled to aid the 5.7 million malnourished ... years in age, Grassroots Features reported. ,Two-and-a-half-year-old Prem ... 4.2 kg when she was brought to the Bal Shakti ...
... to a new study at the University of Michigan Depression ... not getting// any treatment nor are the ones with the ... ,In the latest issue of General Hospital Psychiatry, the ... of treatment, are not getting enough. ,Without adequate treatment ...
... Bill Gates said inadequate access to treatment and continued discrimination ... in addresses to the largest ever AIDS conference under way ... stigma and stop people from being scared to know their ... Gates have donated billions of dollars to combat the spread ...
... the use of Herceptin in advanced breast cancer patients led ... percent of patients treated with Herceptin// , which no ... of the damage to the heart can be remedied with ... in the Journal of Clinical Oncology, concludes that use of ...
... that reduced levels of testosterone, which is the male sex ... whether a man would die early. ,US scientists ... 858 military veterans aged over 40. Reporting their findings in ... low hormone levels had an 88% increased risk of death ...
Cached Medicine News:Health News:Scheme for Combating Malnourishment in MP Children Yet to Pick Up 2Health News:No therapy for most of the pregnant women with depression 2Health News:No therapy for most of the pregnant women with depression 3Health News:No therapy for most of the pregnant women with depression 4Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 2Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 3Health News:Low Testosterone Linked With Early Death 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: